Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes
- 7 December 2011
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 138 (3) , 377-385
Abstract
Purpose The phosphatidylinositol 3-kinase (PI3K)/PTEN/AKT/mTOR and Ras/Raf/MEK/ERK pathways have been implicated in endometrial tumorigenesis. In this candidate pathway analysis, we investigated associations between genetic variations in these two pathways and both risk and clinical outcomes of endometrial cancer. Methods We genotyped a total of 48 potentially functional SNPs in 11 key genes (AKT1, AKT2, AKT3, BRAF, FRAP1, KRAS, PDPK1, PIK3CA, PIK3CB, PIK3R1, and PTEN) with the Sequenom genotyping platform in 115 endometrial cancer patients and 230 cancer-free women to evaluate their associations with risk, survival, and recurrence of endometrial cancer. Results We found the following: (1) PIK3CA rs6443624 and rs9838411 variants either borderline or significantly decreased risk of endometrial cancer in a dominant model (adjusted odds ratio [OR], 0.62; 95% CI, 0.39–1.00 and 0.59; 95% CI, 0.36–0.95, respectively). Furthermore, there was a statistically significant multiplicative interaction (P int = 0.036) between these two loci in risk of endometrial cancer. In contrast, the AKT1 rs2498801 genotype significantly increased risk of endometrial cancer (adjusted OR, 1.94; 95% CI, 1.02–3.67 in a recessive model). (2) In Cox regression analyses, three SNPs (PIK3R1 rs1862162, AKT2 rs892119, and PIK3CA rs2699887) showed significant associations with survival of endometrial cancer patients. (3) KRAS rs7312175 and PIK3CA rs6443624 had significant effects on recurrence of endometrial cancer individually and combined in a locus–dosage manner (adjusted P trend = 0.003). Conclusion These results suggest that common genetic variations in these pathways may modulate risk and clinical outcomes of endometrial cancer. Further replication and functional studies are needed to confirm these findings.Keywords
This publication has 44 references indexed in Scilit:
- The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapyCell Cycle, 2010
- Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP‐9Hepatology Research, 2009
- Akt as a therapeutic target in cancerExpert Opinion on Therapeutic Targets, 2008
- Association between Phosphatidylinositol 3-Kinase Regulatory Subunit p85α Met326Ile Genetic Polymorphism and Colon Cancer RiskClinical Cancer Research, 2008
- The Phosphoinositide 3-Kinase Pathway in Human Cancer: Genetic Alterations and Therapeutic ImplicationsCurrent Genomics, 2007
- CYP19 (aromatase) haplotypes and endometrial cancer riskInternational Journal of Cancer, 2005
- Characterization of the Met326Ile variant of phosphatidylinositol 3-kinase p85αProceedings of the National Academy of Sciences, 2002
- AKT plays a central role in tumorigenesisProceedings of the National Academy of Sciences, 2001
- PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas.2001
- Role of Exogenous and Endogenous Hormones in Endometrial CancerAnnals of the New York Academy of Sciences, 2001